Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression

In conclusion, we have demonstrated that PDGF-BB protects MSCs derived from ITP patients against apoptosis, senescence, and immunomodulatory defects. This protective effect of PDGF-BB is likely mediated via the p53/p21 pathway, thus potentially providing a new therapeutic approach for ITP.

Significance
Immune thrombocytopenia (ITP) is characterized by platelet destruction and megakaryocyte dysfunction. Platelet-derived growth factor (PDGF) improves growth and survival in various cell types and promotes mesenchymal stem cell (MSC) proliferation. PDGF-BB protects MSCs derived from ITP patients against apoptosis, senescence, and immunomodulatory defects. This protective effect of PDGF-BB is likely mediated via the p53/p21 pathway, thus potentially providing a new therapeutic approach for ITP.

Source: Stem Cells Translational Medicine - November 16, 2016 Category: Stem Cells Authors: Zhang, J.-m., Feng, F.-e., Wang, Q.-m., Zhu, X.-l., Fu, H.-x., Xu, L.-p., Liu, K.-y., Huang, X.-j., Zhang, X.-h. Tags: Mesenchymal Stem Cells, Tissue-Specific Progenitor and Stem Cells Source Type: research